Premium
Use of sirolimus‐eluting coronary stents in routine clinical practice
Author(s) -
Goy JeanJacques,
Urban Philip,
Seydoux Charles,
De Benedetti Edoardo,
Stauffer JeanChristophe
Publication year - 2004
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.10744
Subject(s) - medicine , mace , restenosis , sirolimus , randomized controlled trial , stent , target lesion , clinical practice , clinical trial , incidence (geometry) , surgery , angioplasty , revascularization , myocardial infarction , conventional pci , percutaneous coronary intervention , physics , family medicine , optics
Restenosis has long remained the major limitation of intracoronary stenting, but several randomized trials have recently shown that the use of drug‐eluting stents appear to reduce markedly the risk of recurrence following treatment of de novo lesions. To evaluate whether the results of randomized trials can be generalized to routine clinical practice, all patients receiving at least one sirolimus‐eluting stent (SES) in two Swiss hospitals were entered into a prospective registry. Only target vessels with a reference diameter > 3.5 mm were excluded. Clinical follow‐up was obtained after 6 months. A total of 183 patients were included. The procedural success was 97.8% and the incidence of in‐hospital MACE was 2.2%. At 7 ± 2 months, 95.6% of the patients were event‐free, and target lesion revascularization was required in only three patients (1.6%). The excellent medium‐term results obtained with the SES in randomized trials can be replicated in routine clinical practice. Catheter Cardiovasc Interv 2004;62:26–29. © 2004 Wiley‐Liss, Inc.